Calcium in PDB 4r90: Anti CD70 Llama Glama Fab 27B3

The structure of Anti CD70 Llama Glama Fab 27B3, PDB code: 4r90 was solved by A.Klarenbeek, K.El Mazouari, A.Desmyter, C.Blanchetot, A.Hultberg, R.C.Roovers, C.Cambillau, S.Spinelli, J.Del-Favero, T.Verrips, H.Dehaard, I.Achour, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	62.71 / 1.75
Space group	P 21 21 21
Cell size a, b, c (Å), α, β, γ (°)	63.570, 66.880, 125.420, 90.00, 90.00, 90.00
R / Rfree (%)	16.3 / 18.5

The binding sites of Calcium atom in the Anti CD70 Llama Glama Fab 27B3 (pdb code 4r90). This binding sites where shown within 5.0 Angstroms radius around Calcium atom.
In total only one binding site of Calcium was determined in the Anti CD70 Llama Glama Fab 27B3, PDB code: 4r90:

Calcium binding site 1 out of 1 in the Anti CD70 Llama Glama Fab 27B3


Mono view


Stereo pair view

A full contact list of Calcium with other atoms in the Ca binding site number 1 of Anti CD70 Llama Glama Fab 27B3 within 5.0Å range: probe atom residue distance (Å) B Occ H:Ca301 b:35.0 occ:1.00 OD2 H:ASP99 2.8 16.9 1.0 ND2 H:ASN35 2.9 14.5 1.0 OD2 H:ASP50 2.9 21.0 1.0 OD1 H:ASN35 3.4 14.9 1.0 CB H:ASP99 3.4 15.5 1.0 CB H:TYR33 3.5 18.6 1.0 CG H:ASP99 3.5 16.4 1.0 CG H:ASN35 3.5 14.3 1.0 CB H:PRO107 3.7 19.0 1.0 CG H:ASP50 3.7 17.8 1.0 CB H:ASP50 3.7 16.4 1.0 CD1 H:TYR33 3.9 24.2 1.0 CG H:PRO107 3.9 19.4 1.0 CG H:TYR33 4.1 22.1 1.0 O H:HOH635 4.5 45.5 1.0 O H:HOH702 4.5 26.9 1.0 CA H:PRO107 4.5 18.8 1.0 C H:TYR33 4.6 15.0 1.0 CE1 H:PHE109 4.7 16.2 1.0 CA H:TYR33 4.7 16.6 1.0 OD1 H:ASP99 4.7 16.5 1.0 CA H:ASP99 4.7 15.0 1.0 O H:HOH634 4.7 32.3 1.0 O H:TYR33 4.8 14.2 1.0 N H:MET34 4.9 14.1 1.0 OD1 H:ASP50 4.9 18.9 1.0 O H:MET34 4.9 14.0 1.0

A.Klarenbeek, K.E.Mazouari, A.Desmyter, C.Blanchetot, A.Hultberg, N.De Jonge, R.C.Roovers, C.Cambillau, S.Spinelli, J.Del-Favero, T.Verrips, H.J.De Haard, I.Achour. Camelid Ig V Genes Reveal Significant Human Homology Not Seen in Therapeutic Target Genes, Providing For A Powerful Therapeutic Antibody Platform. Mabs V. 7 693 2015.
ISSN: ISSN 1942-0862
PubMed: 26018625
DOI: 10.1080/19420862.2015.1046648